Want To Make Money In Marijuana? / Хотите заработать денег на марихуане?

Contrast Medbox and Cannavest with mCig, Inc., whose business plan fuses two recent cultural curiosities: socially acceptable marijuana use and electronic cigarettes. While an electronic cigarette can theoretically burn any plant material – tobacco, cloves, celery – mCig offers a line of vaporizers marketed just for marijuana use. The company trades over-the-counter, hasn’t made a dime since its inception, and in fact has barely made a sale (revenue of $50,000 over the last three years.) Not coincidentally, over-the-counter and Pink Sheets stocks are the overwhelming rule, not the exception, among marijuana issues. The ones that can consistently stay at prices above $1 are extraordinarily rare, and such relatively high-priced stocks showcased in this article comprise a list that’s just about exhaustive. Furthermore, it barely counts as an observation to point out that it’s effectively impossible to build wealth among the penny stocks that trade on the outskirts of the stock market.

The very phrase “marijuana stock” is limiting, more so than “vending machine stock” or “hydroponic stock” is. Why? Because an upstart pharmaceutical company that restricts itself to making cancer and AIDS drugs exclusively out of cannabinoid derivatives is closing other avenues off to itself. It’s like a grocery that deals only in organic, fair-trade food. The methodology, the mission, and the marketing can end up overshadowing the goods or services offered. Any enterprising cancer drug manufacturer that’s willing to invest in non-hemp-related research and development has a huge competitive advantage over its more ideologically driven counterpart. There comes a point when investors and consumers have to wonder – is hemp truly an integral ingredient in this company’s protein powder, or is the hemp in there solely because the manufacturer is trying to make a point?